The recent study from Burst Biologics challenges existing standards and outlines future safety and potency benchmarks.
The prestigious peer-reviewed journal Regenerative Medicine has announced the publication of the original research article from Burst Biologics (ID, USA) entitled, "Characterization of an umbilical cord blood sourced product suitable for allogeneic applications." The article provides a comprehensive overview of the quality attributes, clinical suitability and efficacy of BioBurst Rejuv, an umbilical cord blood (UCB)-sourced allograft, defined as a tissue graft from a donor of the same species.
Previous research has demonstrated that UCB contains cytokines and growth factors, components that are integral to bone consolidation and tissue repair.
"This current study addresses the unmet need for a uniform quality control framework to determine clinical suitability and safety of cord blood allografts," said Christopher D. Jones, CEO of Burst Biologics and a corresponding author of the paper. "This is the first known published report enumerating the tests to address identity, purity, safety and potency for a UCB sourced allograft."
The study reports on exosome-based therapy, which may be the next quantum leap in regenerative medicine, a field focused on replacing or regenerating human cells, tissue or organs, to restore or establish normal function. The published article identifies a unique liaison among the UCB-sourced allograft, host mesenchymal stem cells (MSCs) and their secreted exosomes that influences tissue regeneration in vivo.
"Based on these findings, clinical suitability of cord blood allografts must account for the non-cellular components while evaluating their promising role in tissue regeneration," stated Jones. "This study brings us one step closer to optimizing the bounds of regenerative medicine."
In the study, the identity of BioBurst Rejuv was established by use of flow cytometry, a mass spectrometry-based proteomic approach and protein multiplexing testing. Microbiological screenings, graft-versus-host disease testing, and endotoxin values were used to assess safety and purity.
The non-cellular components were found to be effective in promoting cell proliferation, migration and neutralizing redox-stress in vivo and MSCs treated with a UCB-sourced allograft demonstrated boosted potential for tissue regeneration. The UCB-sourced allograft was also found to be functionally stable up to 2 years when stored at optimum conditions.
"Burst Biologics has been pioneering research and product development since its inception," said Jones. "We are committed to exploring the unique attributes of UCB components and developing future applications that improve lives."
Read the full research article here: http://www.
For additional information, contact: Erin Taylor: email@example.com
About Regenerative Medicine
Regenerative Medicine (IF: 2.383 (2018)) is part of the internationally recognized Future Medicine portfolio and is supported by a multidisciplinary, international editorial board comprising leading researchers and opinion leaders from academia and industry, including Senior Editor Chris Mason (UCL, UK), and Associate Editors Robert Lanza (Astellas GRM, CA, USA), Phillipe Menasché (Hôpital Européen Georges Pompidou, FR), Gail Naughton (Histogen Inc., CA, USA) and Glyn Stacey (International Stem Cell Banking Initiative, UK).
Regenerative Medicine focuses on the entire spectrum of approaches in regenerative medicine, including small molecule drugs, biologics, biomaterials, tissue engineering, and cell and gene therapies. The peer-reviewed journal uniquely supports this important area of biomedical science and healthcare by publishing the very best research and opinion, encompassing all aspects of the sector ranging from discovery research to clinical development and commercialization.
For additional information on the journal's aims and scope, editorial board and the latest content, please visit the Future Medicine website here: https:/
The journal is also partnered with RegMedNet, a free eCommunity aiming to promote global collaboration between all members of the regenerative medicine field as well as keep users up to date with the latest news and opinion, by providing exclusive features, webinars and more.
About Future Science Group (FSG)
Founded in 2001, Future Science Group is a progressive publisher focused on breakthrough medical, biotechnological and scientific research.
Future Science Group's portfolio consists of three publishing imprints, Future Science, Future Medicine, Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to a core business of subscription and open access journal publishing, Future Science Group develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs.
This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.